|
EP1406873B1
(de)
|
2001-06-27 |
2007-09-26 |
Smithkline Beecham Corporation |
Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
|
|
WO2003068750A1
(en)
*
|
2002-02-13 |
2003-08-21 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
US7074798B2
(en)
|
2002-02-25 |
2006-07-11 |
Eisai Co., Ltd |
Xanthine derivative and DPPIV inhibitor
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
EP1527049B8
(de)
|
2002-08-08 |
2008-10-29 |
Takeda Pharmaceutical Company Limited |
Kondensierte heterozyklische verbindungen als petidase inhibitoren
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
EP1537880A4
(de)
*
|
2002-09-11 |
2009-07-01 |
Takeda Pharmaceutical |
PRûPARAT MIT VERZ GERTER FREISETZUNG
|
|
AU2003289386A1
(en)
*
|
2002-12-18 |
2004-07-09 |
Takeda Pharmaceutical Company Limited |
Jnk inhibitors
|
|
ATE496893T1
(de)
|
2002-12-20 |
2011-02-15 |
X Ceptor Therapeutics Inc |
Isochinolinonderivate und deren verwendung als medikamente
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2004083184A1
(ja)
*
|
2003-03-17 |
2004-09-30 |
Takeda Pharmaceutical Company Limited |
受容体拮抗剤
|
|
EP1608317B1
(de)
*
|
2003-03-25 |
2012-09-26 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidase-hemmer
|
|
EP1625122A1
(de)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidylpeptidase-hemmer
|
|
CA2531856C
(en)
*
|
2003-07-11 |
2013-07-30 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Benzimidazole carboxamides as raf kinase inhibitors
|
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7790736B2
(en)
*
|
2003-08-13 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
WO2005026148A1
(en)
*
|
2003-09-08 |
2005-03-24 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
WO2005030751A2
(en)
*
|
2003-09-08 |
2005-04-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7547693B2
(en)
|
2003-09-22 |
2009-06-16 |
Banyu Pharmaceutical Co. Ltd. |
Piperidine derivative
|
|
JP4719152B2
(ja)
|
2003-09-23 |
2011-07-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
イソキノリノンカリウムチャネル阻害剤
|
|
EP1667981A4
(de)
*
|
2003-09-23 |
2008-08-13 |
Merck & Co Inc |
Isochinoline als kaliumkanalinhibitoren
|
|
CN1856474A
(zh)
*
|
2003-09-23 |
2006-11-01 |
默克公司 |
异喹啉钾通道抑制剂
|
|
MXPA06005518A
(es)
|
2003-11-17 |
2006-08-17 |
Novartis Ag |
Uso de inhibidores de la dipeptidil peptidasa iv.
|
|
NZ578743A
(en)
|
2004-01-20 |
2011-04-29 |
Novartis Ag |
Direct compression formulation and process
|
|
WO2005075421A1
(ja)
*
|
2004-02-05 |
2005-08-18 |
Kyorin Pharmaceutical Co., Ltd. |
ビシクロエステル誘導体
|
|
KR20060129021A
(ko)
*
|
2004-02-18 |
2006-12-14 |
교린 세이야꾸 가부시키 가이샤 |
비시클로아미드 유도체
|
|
US7514571B2
(en)
*
|
2004-02-27 |
2009-04-07 |
Kyorin Pharmaceutical Co., Ltd. |
Bicyclo derivative
|
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
EA013427B1
(ru)
*
|
2004-03-15 |
2010-04-30 |
Такеда Фармасьютикал Компани Лимитед |
Ингибиторы дипептидилпептидазы
|
|
CN1938286A
(zh)
|
2004-03-29 |
2007-03-28 |
默克公司 |
作为11-β-羟甾类脱氢酶-1抑制剂的二芳基三唑
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
US7687638B2
(en)
*
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
US7915252B2
(en)
|
2004-08-06 |
2011-03-29 |
Merck Sharp & Dohme |
Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
|
AR050615A1
(es)
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
|
ES2519690T3
(es)
*
|
2004-09-24 |
2014-11-07 |
University Of Maryland, Baltimore |
Método de tratamiento de envenenamiento por organosfósforo
|
|
US9132135B2
(en)
*
|
2004-09-24 |
2015-09-15 |
University Of Maryland, Baltimore |
Method of treating organophosphorous poisoning
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
US7872124B2
(en)
*
|
2004-12-21 |
2011-01-18 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
EP2602259A3
(de)
|
2005-02-18 |
2014-09-10 |
Mitsubishi Tanabe Pharma Corporation |
Salz des Prolinderivats, Solvat davon und Herstellungsverfahren dafür
|
|
BRPI0608469A2
(pt)
|
2005-04-22 |
2010-01-05 |
Alantos Pharmaceuticals Holding Inc |
inibidores de dipeptidil peptidase-iv
|
|
JP5100375B2
(ja)
*
|
2005-04-26 |
2012-12-19 |
田辺三菱製薬株式会社 |
糖・脂質代謝異常の予防及び/又は治療薬
|
|
BRPI0610580B8
(pt)
|
2005-05-30 |
2021-05-25 |
Banyu Pharma Co Ltd |
composto derivado de piperidina
|
|
ATE550031T1
(de)
|
2005-06-06 |
2012-04-15 |
Univ Georgetown |
Zusammensetzungen und verfahren für die lipomodellierung
|
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
|
EP1916239A4
(de)
|
2005-08-10 |
2009-10-21 |
Banyu Pharma Co Ltd |
Pyridolverbindung
|
|
CA2617715A1
(en)
*
|
2005-08-11 |
2007-02-15 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition comprising a dpp-iv inhibitor
|
|
DE602006017712D1
(de)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
Phenylpyridonderivat
|
|
US20090264426A1
(en)
|
2005-09-07 |
2009-10-22 |
Shunji Sakuraba |
Bicyclic aromatic substituted pyridone derivative
|
|
JP5027137B2
(ja)
|
2005-09-14 |
2012-09-19 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤の投与
|
|
CN102908351B
(zh)
*
|
2005-09-14 |
2014-07-23 |
武田药品工业株式会社 |
用于治疗糖尿病的二肽基肽酶抑制剂
|
|
KR101368988B1
(ko)
*
|
2005-09-16 |
2014-02-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
디펩티딜 펩티다제 억제제
|
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
|
KR20080048502A
(ko)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
|
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
|
AU2006312557B2
(en)
|
2005-11-10 |
2011-12-08 |
Msd K.K. |
Aza-substituted spiro derivative
|
|
US9101160B2
(en)
|
2005-11-23 |
2015-08-11 |
The Coca-Cola Company |
Condiments with high-potency sweetener
|
|
EP1801098A1
(de)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
|
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
JP5101489B2
(ja)
*
|
2006-03-08 |
2012-12-19 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体
|
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
WO2007112368A1
(en)
*
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
|
CN109503584A
(zh)
|
2006-05-04 |
2019-03-22 |
勃林格殷格翰国际有限公司 |
多晶型
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
|
EP2083831B1
(de)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Verfahren zur behandlung von fettsäure-synthese-hemmern
|
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
US8017168B2
(en)
|
2006-11-02 |
2011-09-13 |
The Coca-Cola Company |
High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
|
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
EP1935420A1
(de)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
|
|
CN101583601B
(zh)
*
|
2007-01-17 |
2013-06-05 |
香港科技大学 |
作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
|
|
US9604931B2
(en)
|
2007-01-22 |
2017-03-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
|
US9623021B2
(en)
|
2007-01-22 |
2017-04-18 |
Gtx, Inc. |
Nuclear receptor binding agents
|
|
CA2676066C
(en)
|
2007-01-22 |
2016-06-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
|
JPWO2008114857A1
(ja)
*
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
|
WO2008137105A1
(en)
|
2007-05-07 |
2008-11-13 |
Merck & Co., Inc. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2009110510A1
(ja)
|
2008-03-06 |
2009-09-11 |
萬有製薬株式会社 |
アルキルアミノピリジン誘導体
|
|
JPWO2009119726A1
(ja)
|
2008-03-28 |
2011-07-28 |
Msd株式会社 |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
EP2108960A1
(de)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
|
|
EP2110374A1
(de)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
|
|
JPWO2009154132A1
(ja)
|
2008-06-19 |
2011-12-01 |
Msd株式会社 |
スピロジアミン−ジアリールケトオキシム誘導体
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
WO2010013595A1
(ja)
|
2008-07-30 |
2010-02-04 |
萬有製薬株式会社 |
5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
WO2010016584A1
(ja)
*
|
2008-08-07 |
2010-02-11 |
杏林製薬株式会社 |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
|
US20110152342A1
(en)
*
|
2008-08-14 |
2011-06-23 |
Hiroshi Uchida |
Stabilized pharmaceutical composition
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
MX2011004258A
(es)
|
2008-10-22 |
2011-06-01 |
Merck Sharp & Dohme |
Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
|
|
MX2011004551A
(es)
|
2008-10-30 |
2011-05-25 |
Merck Sharp & Dohme |
Antagonistas del receptor de orexina de isonicotinamida.
|
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
|
EP2344519B1
(de)
|
2008-11-07 |
2016-09-28 |
The General Hospital Corporation |
C-terminale fragmente von glucagon-ähnlichem peptid-1 (glp-1)
|
|
JP5514831B2
(ja)
|
2008-11-17 |
2014-06-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病の治療のための置換二環式アミン
|
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
CA2768577A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
JP2013510834A
(ja)
|
2009-11-16 |
2013-03-28 |
メリテク |
[1,5]‐ジアゾシン誘導体
|
|
NZ599298A
(en)
|
2009-11-27 |
2014-11-28 |
Boehringer Ingelheim Int |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP2013523819A
(ja)
|
2010-04-06 |
2013-06-17 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
|
|
KR101927068B1
(ko)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
CN103539791B
(zh)
|
2010-09-22 |
2017-01-11 |
艾尼纳制药公司 |
Gpr119 受体调节剂和对与其相关的障碍的治疗
|
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
EP2677869B1
(de)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Neue cyclische azabenzimidazolderivate als antidiabetika
|
|
KR102034748B1
(ko)
|
2011-03-01 |
2019-10-21 |
시너지 파마슈티컬즈 인코포레이티드 |
구아닐레이트 사이클라제 c 작용제의 제조 방법
|
|
CN102190641A
(zh)
*
|
2011-03-23 |
2011-09-21 |
四川科伦药物研究有限公司 |
一种制备西酞普兰和艾司西酞普兰关键中间体的方法
|
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
EP2729157B1
(de)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
|
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
EP3685839A1
(de)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
|
|
EP4151218A1
(de)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
CA2880901A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
|
MX2015010935A
(es)
|
2013-02-22 |
2015-10-29 |
Merck Sharp & Dohme |
Compuestos biciclicos antidiabeticos.
|
|
EP2970119B1
(de)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Neuartige indolderivate als antidiabetika
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
HK1220611A1
(zh)
|
2013-03-15 |
2017-05-12 |
Bausch Health Ireland Limited |
用於治疗胃肠道病症的组成物
|
|
EP3004138B1
(de)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
|
CA2959208C
(en)
|
2014-08-29 |
2023-09-19 |
Tes Pharma S.R.L. |
Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
|
|
KR20180006881A
(ko)
|
2015-03-09 |
2018-01-19 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
|
WO2017003723A1
(en)
|
2015-07-01 |
2017-01-05 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
|
EP4233840A3
(de)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Kombinationen aus linagliptin und metformin
|
|
CA3038185A1
(en)
|
2016-10-14 |
2018-04-19 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
|
WO2018187350A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
|
|
US11028068B2
(en)
|
2017-07-25 |
2021-06-08 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
|
EP3883930A1
(de)
|
2018-11-20 |
2021-09-29 |
Tes Pharma S.r.l. |
Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase
|
|
EP3923933A4
(de)
|
2019-02-13 |
2022-08-17 |
Merck Sharp & Dohme Corp. |
Pyrrolidinorexin-rezeptor-agonisten
|
|
EP3924058B1
(de)
|
2019-02-13 |
2026-01-07 |
Merck Sharp & Dohme LLC |
5-alkyl-pyrrolidinorexinrezeptor-agonisten
|
|
US12312332B2
(en)
|
2019-08-08 |
2025-05-27 |
Merck Sharp & Dohme Llc |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
US11680060B2
(en)
|
2020-08-18 |
2023-06-20 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|